Baisong Mei, a veteran of Sanofi and Biogen, comes to Editas half a year after the gene editing company fired his predecessor and one month after new CEO Gilmore O'Neill started on the job.

Better understanding patient cohorts can shed light on outcomes, but what if coding doesn’t exist?

The regulator said there have been “a few” spontaneous severe allergic reactions following administration of the vaccine, which was this week authorized in the U.S.

In exchange for $500 million, the fund, called OMERS, will get a 30% royalty on future sales of Ultragenyx’s drug Crysvita in the U.S. and Canada, where it’s approved to treat two rare conditions.

The Danish drugmaker will buy a priority review voucher from Marinus Pharmaceuticals, the latest in a string of similarly priced purchases.

The initiative aims to address inflationary pressures and prevent worse health outcomes down the line, CEO Andrew Witty told investors Friday.

A shaky biotech market has forced another drugmaker to adjust, with CytomX revealing plans to reduce its workforce by 40%.

The prolific biopharma dealmaker is paying Theravance $1.1 billion and Innoviva $282 million to acquire rights to royalties on GSK’s asthma and COPD drug Trelegy Ellipta.

The deferral puts the drug in regulatory limbo, setting back the Swiss pharma's efforts to catch up to top immunotherapy developers Merck, Bristol Myers Squibb and Roche.

The shot is the first of its type authorized for COVID-19 by the FDA, but faces an uncertain future due to questions about its ability to fight omicron as well as the biotech’s ability to manufacture large quantities. 

Too few investors in the women’s health company pledged their shares to the take-private offer from EW Healthcare Partners, forcing the deal’s termination.

Much-anticipated interim results from Atara’s Phase 2 study revealed little about the likelihood of the trial’s success, spurring a market sell-off.